NDAORALTABLET
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
6/8 — Strong
UPTRAVI (selexipag) by Johnson & Johnson is prostacyclin receptor agonists [moa]. Approved for pulmonary hypertension. First approved in 2015.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UPTRAVI (selexipag) is an oral prostacyclin receptor agonist approved by the FDA in December 2015 for the treatment of pulmonary arterial hypertension (PAH). It works by selectively binding to the prostacyclin receptor, promoting vasodilation and reducing platelet aggregation. The drug represents a key oral therapeutic option in the PAH treatment landscape, offering an alternative mechanism to endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
$0.8BPart D
11.1 years to LOEMechanism of Action
Prostacyclin Receptor Agonists
Pharmacologic Class:
Prostacyclin Receptor Agonist
Indications (1)
Clinical Trials (3)
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Started Oct 2020
20 enrolled
Pulmonary HypertensionSchistosomiasis
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
Started Oct 2020
372 enrolled
Pulmonary Arterial Hypertension
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
Started May 2017
0Pulmonary Arterial Hypertension
Worked on UPTRAVI at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.